Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.26 SEK -0.1% Market Closed
Market Cap: 663.5m SEK
Have any thoughts about
Orexo AB?
Write Note

EV/EBIT
Enterprise Value to EBIT

-20
Current
-4.8
Median
16.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-20
=
Enterprise Value
1B SEK
/
EBIT
-50.8m SEK
All Countries
Close
Market Cap EV/EBIT
SE
Orexo AB
STO:ORX
663.5m SEK -20
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 11.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 253.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 15.8
EBIT Growth EV/EBIT to Growth
SE
Orexo AB
STO:ORX
Average EV/EBIT: 2 010.8
Negative Multiple: -20
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-16.6
2-Years Forward
EV/EBIT
-9.7
3-Years Forward
EV/EBIT
67.6

See Also

Discover More